Alan Crane

Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies.

He has served as founder, chairman, and/or CEO in building eight Polaris companies. His current and past portfolio include: Momenta Pharmaceuticals, Visterra, Navitor Pharmaceuticals, Dyno Therapeutics, Pandion Therapeutics, KSQ Therapeutics, T2 Biosystems, Ocular Therapeutix, Sirtris Pharmaceuticals, Adnexus Therapeutics, Arsia Therapeutics, Seventh Sense Biosystems, Cerulean Pharma, and XTuit Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.